Neilanjan Nandi

Dr. Hanauer is the Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University’s Feinberg School of Medicine since 2014. Dr. Hanauer received his medical degree from the University of Illinois Chicago, and he completed his residency in internal medicine and a fellowship in gastroenterology at the University of Chicago in 1982. In 2014, Dr. Hanauer was named the Medical Director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine in the Northwestern University’s Feinberg School of Medicine, where he continues to treat IBD patients and conducts research into new therapies.

Dr. Hanauer is a Fellow and past President of the American College of Gastroenterology (ACG) and the former Chair of the American Gastroenterological Association’s Inflammation, Immunology, and IBD Section. In October 2020, received the Master of the American College of Gastroenterology.

Internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs. Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of most of the leading IBD therapies.

Dr. Hanauer has authored over 500 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials. He has been a reviewer for NEJM, Annals of Internal Medicine, Lancet, Gastroenterology and numerous specialty journals.

Neilanjan Nandi, MD, FACG, AGAF, FCCF, FACP is an Associate Professor of Clinical Medicine at the Perelman School of Medicine, University of Pennsylvania and is the Co-Section Head and Direcotr of Clinical Operations of the University of Pennsylvania Inflammatory Bowel Disease Program. Dr. Nandi specializes in the complex management of Crohn's disease, Ulcerative Colitis and recurrent C. difficile infection (C difficile). He has also authored numerous abstracts, publications and book chapters on the diagnosis and management of IBD, C difficile and various viral, parasitic, mycobacterial and bacterial infections of the GI tract. Aligning with his interests, Dr. Nandi has conducted several clinical trials focused on the clinical impact of stool derived microbiome therapies in C difficile and IBD. Dr. Nandi servies on the Philadelphia/Delaware Valley Crohn's & Colitis Foundation (CCF) Executive Council and on the Medical Advisory Board of the United Ostomy Associates of America (UOAA). He is a founding non-profit board member and Chair of the South Asian IBD Alliance (SAIA) which elevates culturally competent care in South Asian IBD. He has been recognized with the 2019 Philly Take STeps Physician Hero, the 2022 CCF's National Chairman’s Citation Award and the 2024 CCF's Gold Medallion Physician Award. He is the honored recipient of the 2023 Sidney Cohen GI Faculty Teaching Award and the 2024 Radhika Srinivasan GI Faculty award for Professionalism and Humanism at the Perelman School of Medicine.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Neilanjan Nandi, MD, FACG, AGAF, FCCF, FACP is an Associate Professor of Clinical Medicine at the Perelman School of Medicine, University of Pennsylvania and is the Co-Section Head and Direcotr of Clinical Operations of the University of Pennsylvania Inflammatory Bowel Disease Program. Dr. Nandi specializes in the complex management of Crohn's disease, Ulcerative Colitis and recurrent C. difficile infection (C difficile). He has also authored numerous abstracts, publications and book chapters on the diagnosis and management of IBD, C difficile and various viral, parasitic, mycobacterial and bacterial infections of the GI tract. Aligning with his interests, Dr. Nandi has conducted several clinical trials focused on the clinical impact of stool derived microbiome therapies in C difficile and IBD. Dr. Nandi servies on the Philadelphia/Delaware Valley Crohn's & Colitis Foundation (CCF) Executive Council and on the Medical Advisory Board of the United Ostomy Associates of America (UOAA). He is a founding non-profit board member and Chair of the South Asian IBD Alliance (SAIA) which elevates culturally competent care in South Asian IBD. He has been recognized with the 2019 Philly Take STeps Physician Hero, the 2022 CCF's National Chairman’s Citation Award and the 2024 CCF's Gold Medallion Physician Award. He is the honored recipient of the 2023 Sidney Cohen GI Faculty Teaching Award and the 2024 Radhika Srinivasan GI Faculty award for Professionalism and Humanism at the Perelman School of Medicine.

Jessiy Salwen-Deremer, Ph.D., DBSM, is the Director of Behavioral Medicine for Digestive Health at Dartmouth-Hitchcock Medical Center and Assistant Professor of Psychiatry & Medicine at the Geisel School of Medicine at Dartmouth. Dr. Salwen-Deremer earned her Ph.D. in clinical psychology at Stony Brook University and completed her fellowship training in behavioral medicine at the Johns Hopkins School of Medicine. Her areas of clinical expertise include behavioral sleep medicine and gastropsychology. Her research expertise encompasses two areas: understanding the impact of sleep disorders on inflammatory bowel diseases and improving access to gastrointestinal behavioral health care. Across both of these areas, she focuses on the integration of telehealth and remote technologies to enhance patient engagement and participation.

Dr. Aline Charabaty is Professor of Medicine at the University of Maryland and the Director of the IBD Program at the University of Maryland Medical center. She is the Editor-in-Chief of the Crohn’s and Colitis 360 journal, and is past Vice-Chair of the AGA Research Foundation Executive Board, and past ACG Governor for Washington DC. Her work and advocacy were recognized by the Crohn’s and Colitis Foundation Excellence in Medicine Award in 2020 , the ACG Diversity Equity and Inclusion Award in 2025, and the AGA Beacon of Hope Award in 2026. Dr Charabaty uses social media to amplify medical education in IBD and is the founder of @MondayNightIBD a CME platform on twitter for which she received the Healio Disruptive Innovator Award in 2019. Dr Charabaty is a strong advocate for diversity and the professional advancement of women in GI. She is the Co-Founder of Scrubs & Heels, a foundation focused on empowering women in GI with the leadership skills, networking and mentorship to achieve professional goals and growth.

Kelly Issokson, MS, RD, CSDH, LDN, CNSC is the Senior Registered Dietitian of Outpatient Nutrition at the University of California, San Francisco (UCSF) and a nationally recognized expert in gastrointestinal nutrition. With over 17 years of clinical experience, she specializes in inflammatory bowel disease (IBD) and surgical nutrition. Ms. Issokson graduated magna cum laude from Johnson & Wales University and earned her MS in Nutrition from California State University, Northridge. She serves on the National Board of the Crohn’s & Colitis Foundation and is a leading voice in advancing nutrition as part of multidisciplinary IBD care. She co-developed the Cedars-Sinai IBD Prehabilitation Program and nutrition education training programs for physicians, APPs, and RDs.

Gil Y. Melmed, MD, MS, is the Clinical Director of the Inflammatory Bowel Disease Program and Associate Director of the Karsh Division of Digestive and Liver Diseases at Cedars-Sinai Medical Center in Los Angeles, California. He earned his medical degree from Albert Einstein College of Medicine in the Bronx, New York, and master of science in clinical research from UCLA School of Medicine, Los Angeles. Dr Melmed completed his gastroenterology fellowship at the University of California, Los Angeles.
He has authored or coauthored more than 250 articles in peer-reviewed journals and several book chapters. Dr Melmed has served as Associate Editor of the American Journal of Gastroenterology, an ad hoc reviewer for several journals, and clinical research editor for Inflammatory Bowel Disease. His research interests include clinical outcomes and quality of care in IBD. He has given invited lectures and presentations nationally and internationally on several clinical topics in inflammatory bowel disease, including quality of care and clinical outcomes. He is a committee member of several professional organizations, including the American College of Gastroenterology and the Crohn’s and Colitis Foundation, where he serves as co-chair of the IBD Quality of Care committee. He has led or participated in the development of quality measures for IBD with the American Gastroenterology Association, the Crohn’s and Colitis Foundation, and the Canadian Crohn’s and Colitis organizations.

Neilanjan Nandi, MD, FACG, AGAF, FCCF, FACP is an Associate Professor of Clinical Medicine at the Perelman School of Medicine, University of Pennsylvania and is the Co-Section Head and Direcotr of Clinical Operations of the University of Pennsylvania Inflammatory Bowel Disease Program. Dr. Nandi specializes in the complex management of Crohn's disease, Ulcerative Colitis and recurrent C. difficile infection (C difficile). He has also authored numerous abstracts, publications and book chapters on the diagnosis and management of IBD, C difficile and various viral, parasitic, mycobacterial and bacterial infections of the GI tract. Aligning with his interests, Dr. Nandi has conducted several clinical trials focused on the clinical impact of stool derived microbiome therapies in C difficile and IBD. Dr. Nandi servies on the Philadelphia/Delaware Valley Crohn's & Colitis Foundation (CCF) Executive Council and on the Medical Advisory Board of the United Ostomy Associates of America (UOAA). He is a founding non-profit board member and Chair of the South Asian IBD Alliance (SAIA) which elevates culturally competent care in South Asian IBD. He has been recognized with the 2019 Philly Take STeps Physician Hero, the 2022 CCF's National Chairman’s Citation Award and the 2024 CCF's Gold Medallion Physician Award. He is the honored recipient of the 2023 Sidney Cohen GI Faculty Teaching Award and the 2024 Radhika Srinivasan GI Faculty award for Professionalism and Humanism at the Perelman School of Medicine.

Jessiy Salwen-Deremer, Ph.D., DBSM, is the Director of Behavioral Medicine for Digestive Health at Dartmouth-Hitchcock Medical Center and Assistant Professor of Psychiatry & Medicine at the Geisel School of Medicine at Dartmouth. Dr. Salwen-Deremer earned her Ph.D. in clinical psychology at Stony Brook University and completed her fellowship training in behavioral medicine at the Johns Hopkins School of Medicine. Her areas of clinical expertise include behavioral sleep medicine and gastropsychology. Her research expertise encompasses two areas: understanding the impact of sleep disorders on inflammatory bowel diseases and improving access to gastrointestinal behavioral health care. Across both of these areas, she focuses on the integration of telehealth and remote technologies to enhance patient engagement and participation.

Dr. Aline Charabaty is Professor of Medicine at the University of Maryland and the Director of the IBD Program at the University of Maryland Medical center. She is the Editor-in-Chief of the Crohn’s and Colitis 360 journal, and is past Vice-Chair of the AGA Research Foundation Executive Board, and past ACG Governor for Washington DC. Her work and advocacy were recognized by the Crohn’s and Colitis Foundation Excellence in Medicine Award in 2020 , the ACG Diversity Equity and Inclusion Award in 2025, and the AGA Beacon of Hope Award in 2026. Dr Charabaty uses social media to amplify medical education in IBD and is the founder of @MondayNightIBD a CME platform on twitter for which she received the Healio Disruptive Innovator Award in 2019. Dr Charabaty is a strong advocate for diversity and the professional advancement of women in GI. She is the Co-Founder of Scrubs & Heels, a foundation focused on empowering women in GI with the leadership skills, networking and mentorship to achieve professional goals and growth.

Kelly Issokson, MS, RD, CSDH, LDN, CNSC is the Senior Registered Dietitian of Outpatient Nutrition at the University of California, San Francisco (UCSF) and a nationally recognized expert in gastrointestinal nutrition. With over 17 years of clinical experience, she specializes in inflammatory bowel disease (IBD) and surgical nutrition. Ms. Issokson graduated magna cum laude from Johnson & Wales University and earned her MS in Nutrition from California State University, Northridge. She serves on the National Board of the Crohn’s & Colitis Foundation and is a leading voice in advancing nutrition as part of multidisciplinary IBD care. She co-developed the Cedars-Sinai IBD Prehabilitation Program and nutrition education training programs for physicians, APPs, and RDs.

Gil Y. Melmed, MD, MS, is the Clinical Director of the Inflammatory Bowel Disease Program and Associate Director of the Karsh Division of Digestive and Liver Diseases at Cedars-Sinai Medical Center in Los Angeles, California. He earned his medical degree from Albert Einstein College of Medicine in the Bronx, New York, and master of science in clinical research from UCLA School of Medicine, Los Angeles. Dr Melmed completed his gastroenterology fellowship at the University of California, Los Angeles.
He has authored or coauthored more than 250 articles in peer-reviewed journals and several book chapters. Dr Melmed has served as Associate Editor of the American Journal of Gastroenterology, an ad hoc reviewer for several journals, and clinical research editor for Inflammatory Bowel Disease. His research interests include clinical outcomes and quality of care in IBD. He has given invited lectures and presentations nationally and internationally on several clinical topics in inflammatory bowel disease, including quality of care and clinical outcomes. He is a committee member of several professional organizations, including the American College of Gastroenterology and the Crohn’s and Colitis Foundation, where he serves as co-chair of the IBD Quality of Care committee. He has led or participated in the development of quality measures for IBD with the American Gastroenterology Association, the Crohn’s and Colitis Foundation, and the Canadian Crohn’s and Colitis organizations.